Chi-Med Starts First US Trial of Fruquintinib, an Anti-Angiogenesis Drug

23:51 EST 15 Dec 2017 | ChinaBio Today

Hutchison China MediTech (Chi-Med) announced the start of a US Phase I bridging trial of its lead drug, fruquintinib, in patients with solid tumor cancers. Fruquintinib is a VEGFR inhibitor with an anti-angiogenesis mechanism. In China, Chi-Med has completed all three clinical trial phases of fruquintinib and filed for market approval in colorectal cancer patients. In 2013, Lilly partnered China rights to fruquintinib with Chi-Med in an $86 million deal, though so far, it has not extended that agreement to the rest of the world. More details....

Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY)

Share this with colleagues:

Original Article: Chi-Med Starts First US Trial of Fruquintinib, an Anti-Angiogenesis Drug


More From BioPortfolio on "Chi-Med Starts First US Trial of Fruquintinib, an Anti-Angiogenesis Drug"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...